LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report report published on Tuesday.

LMAT has been the topic of a number of other reports. Barrington Research raised their target price on LeMaitre Vascular from $66.00 to $69.00 and gave the company an outperform rating in a research note on Wednesday, February 28th. KeyCorp started coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a sector weight rating on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $68.20.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $62.62 on Tuesday. The firm has a market capitalization of $1.40 billion, a PE ratio of 46.73, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. LeMaitre Vascular has a one year low of $44.27 and a one year high of $74.64. The company has a 50-day simple moving average of $65.06 and a 200-day simple moving average of $57.79.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. The company had revenue of $48.90 million during the quarter, compared to the consensus estimate of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. LeMaitre Vascular’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.25 earnings per share. Equities analysts forecast that LeMaitre Vascular will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend was Wednesday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s dividend payout ratio is currently 47.76%.

Insiders Place Their Bets

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares in the company, valued at $358,357.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now directly owns 2,278 shares in the company, valued at $157,182. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 114,036 shares of company stock worth $7,873,749. 12.40% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in shares of LeMaitre Vascular by 0.8% in the third quarter. BlackRock Inc. now owns 3,267,883 shares of the medical instruments supplier’s stock valued at $165,616,000 after buying an additional 26,787 shares in the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of LeMaitre Vascular by 0.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock valued at $109,432,000 after acquiring an additional 10,390 shares in the last quarter. Vanguard Group Inc. boosted its stake in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after purchasing an additional 38,303 shares during the period. Copeland Capital Management LLC grew its position in LeMaitre Vascular by 2.3% during the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock worth $71,515,000 after purchasing an additional 28,720 shares in the last quarter. Finally, Ranger Investment Management L.P. raised its stake in LeMaitre Vascular by 1.5% during the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the period. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.